This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
WORCESTER, Mass. and
May 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine. The following distinguished investigators join Dr.
Gabriel N. Hortobagyi, MD, FACP (
University of Texas MD Anderson Cancer Center), Dr.
Kathy D. Miller, MD (
Indiana University School of Medicine Melvin and Bren Simon Cancer Center), and Dr.
Hope S. Rugo, MD (
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center) on the SAB:
Dr. Keith L. Knutson. PhD Associate Professor, Department of ImmunologyMayo Clinic
Dr. Knutson's current interests and research focus on the immunology and immunotherapy of breast and ovarian cancers, both the basic immunobiology and clinical translation, including clinical trials. His laboratory research on cancer vaccines focuses on augmenting CD4 helper T cell immunity using peptide epitopes. These vaccine strategies are aimed at preventing patients from relapsing after optimal conventional therapies. Adoptive T cell therapy is also being examined, a strategy that involves infusing high numbers of T cells into patients with active bulky malignancy.
In addition to his research, Dr. Knutson participates in and chairs several study sections; is Director of the Mayo Clinic Cancer Center Immunology and Immunotherapy Program; Co-director, Mayo Clinic Immune Monitoring Core; and Director, Ovarian Cancer Immunotherapy Program at Mayo Clinic.
Dr. Knutson received his PhD from the
University of Georgia in Physiology and Pharmacology in 1995 and completed two post-doctoral fellowships in immunology: one at the
University of British Columbia; and the other at the
University of Washington. He was a 2004 recipient of a
Howard Temin Award from the National Cancer Institute.
Dr. James J. MuleMoffitt Cancer Center
Dr. Mule is the Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center.